Table 2.
Percent change from baseline at 6 and 12 months in clinical characteristics and levels of adipokines and biomarkers of inflammation and oxidative stress from cohort 1 (N = 39)
| 6 months Mean % change (95%CI) |
12 months Mean % change (95%CI) |
Baseline vs. 6 months p-value | Baseline vs. 12 months p-value | |
|---|---|---|---|---|
| Weight (kg) | −27.3% (−26.0 to 28.6%) |
−32.4% (−30.5 to −34.4%) |
p<0.001 | p<0.001 |
| BMI (kg/m2) | −27.3% (−25.9 to −28.7%) |
−32.6% (−30.8 to −34.7%) |
p<0.001 | p<0.001 |
| Glucose (mg/dL) | −5.4% (11.4 to −13.8%) |
−9.3% (−5.0 to −13.4%) |
p=0.233 | p<0.001 |
| Insulin (μU/mL) | −57.7% (−49.0 to −65.5%) |
−66.4% (−59.8 to −71.6%) |
p<0.001 | p<0.001 |
| HOMA-IR | −61.1% (−52.8 to −68.1%) |
−68.8% (−62.2 to −74.2%) |
p<0.001 | p<0.001 |
| IL-6 (pg/mL) | −16.7% (16.2 to −39.9%) |
−43.1% (−15.6 to −61.8%) |
p=0.045 | p=0.008 |
| TNF-α (pg/mL) | 19.4% (59.1 to −4.4%) |
7.5% (−44.2 to 15.5%) |
p=0.751 | p=0.213 |
| Leptin (ng/mL) | −57.6% (−39.6 to −70.9%) |
−60.6% (−45.5% to −73.2%) |
p=0.001 | p=0.001 |
| MCP-1 (pg/mL) | −3.7% (6.5 to −13.9% |
−11.8% (3.7 to −19.9%) |
p=0.221 | p=0.160 |
| Resistin ng/mL) | 6.1% (17.5 to −4.7%) |
3.4% (12.9 to −5.3%) |
p=0.983 | p=0.599 |
| OxLDL (U/L) | −5.1% (3.4 to −13.8%) |
−12.5% (−6.4 to −18.5%) |
p=0.072 | p=0.001 |
| Adiponectin (μg/mL) | 107.6% (159.8 to 70.1%) |
153.7% (198.0 to 115.3%) |
p<0.001 | p<0.001 |
Data are presented as mean ± standard deviation. IL-6 = interleukin-6; TNF-α = tumor necrosis factor-alpha; MCP-1 = monocyte chemo-attractant protein-1; OxLDL = oxidized LDL cholesterol